Introduction {#s1}
============

Electroconvulsive therapy (ECT), which is also known as electroshock therapy, is an effective treatment procedure for major mental disorders, including schizophrenia, bipolar disorder and major depressive disorder (MDD).[@R1] General anaesthesia renders unconscious patients free from muscle paralysis and/or even recall and is wildly applied to all ECT procedures in clinical practice.[@R2] Duration of seizure activity, recovery and haemodynamic parameters could be affected by the choice of anaesthetic agent for ECT. Thus, there is a need to determine the optimal choice of anaesthetic agent for ECT from several agents, including ketamine, propofol, etomidate, sevoflurane, ethohexital and thiopental.[@R3]

Ketamine is an N-methyl-D-aspartate (NMDA) antagonist with a rapid antidepressant effect.[@R4] Despite its risk of potential adverse drug reactions (ADRs),[@R6] increasing randomised controlled trials (RCTs) have reported that ketamine was significantly superior to placebo in reducing depressive symptoms in patients with unipolar or bipolar depression.[@R7] Ketamine is often used in ECT and can cause a favourable seizure outcome by inducing action and increasing seizure duration.[@R12] However, ketamine could cause delayed recovery, as well as induce transitory psychotic episodes and cardiotoxicity.[@R14]

Given the correlation of propofol with reasonable haemodynamic response to ECT, it has become increasingly popular in ECT anaesthesia.[@R15] However, propofol has limitations with respect to reduced seizure duration and increased seizure threshold.[@R16] The combination of ketamine and propofol has been successfully employed for various anaesthetic procedures.[@R2] This could be attributed to the following: (1) ketamine can mitigate propofol-related hypotension and (2) propofol can mitigate ketamine-induced recovery agitation and vomiting. Thus, the use of the combination of propofol and ketamine has theoretical benefits, including obviating the need for opioid coadministration and minimising the propofol dose.

There have been several RCTs[@R12] on the use of ketamine alone or ketamine plus propofol in a single ECT treatment session for patients with MDD; however, they have reported inconsistent findings. A recent meta-analysis of seventeen RCTs found that ketamine alone did not increase the antidepressant ECT effect; moreover, ketamine combined with other anaesthetics has a short-term advantage with respect to improvement of depressive symptoms at the early ECT stages[@R20]. These findings are consistent with those of another meta-analysis.[@R21] However, this meta-analysis[@R20] did not include RCTs with a single ECT session.[@R12] Notably, there has been no systematic review or meta-analysis exclusively investigating the effectiveness and safety of adjunctive ketamine with single ECT treatment in patients with MDD. Thus, we aimed to perform a meta-analysis to examine the effectiveness and safety of ketamine alone and that of ketamine combined with propofol in patients with MDD undergoing a single ECT treatment.

Methods {#s2}
=======

Search strategy {#s2-1}
---------------

This meta-analysis was conducted in accordance with the recommendations of the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) checklist.[@R22] As recommended by recent meta-analyses,[@R23] English (PubMed, Embase, PsycINFO and Cochrane Library databases) and Chinese (China National Knowledge Infrastructure and Wanfang database) databases were independently searched by two reviewers (X-ML and Z-MS) on the same day to retrieve studies published in Chinese and English journals from their inception to 23 July 2019 using the following search strategy: ('depression'(MeSH) OR depressive OR depressed OR depression) AND ('electroconvulsive therapy'(MeSH) OR ECT OR electroconvulsive therapy) AND (NMDA OR ketamine OR glutamat\*OR N-methyl-D-aspartic acid) AND ('propofol'(MeSH) OR propofol). Reference lists of the retrieved trials,[@R20] relevant reviews and meta-analyses were manually searched to obtain missing RCTs.

Eligibility criteria {#s2-2}
--------------------

The inclusion criteria were as per the following PICOS acronym: *p*articipants: patients with MDD diagnosed using any criteria; *i*ntervention versus *c*omparison: (1) ketamine alone versus propofol alone in ECT and (2) ketamine + propofol versus propofol alone in ECT; *o*utcomes: the primary outcome was the improvement of depressive symptoms at day 1 after a single ECT treatment measured using standardised rating scales (including the Montgomery and Asberg Depression Rating Scale[@R29] or the Hamilton Depression Rating Scale (HAMD)).[@R31] As recommended by a previous meta-analysis, HAMD was preferred to other scales in studies using multiple rating scales.[@R27] Key secondary outcomes were (1) improvement of depressive symptom at days 3 and 7 after a single ECT session; (2) the improvement of suicide ideation; (3) seizure duration and recovery times, and (4) ADRs. *S*tudy design: only RCT with a single ECT session. Studies with multiple ECT sessions (≥2 times) were excluded.[@R33] Observational studies, conference articles, case report/series and meta-analyses and systematic reviews were excluded. Moreover, multiple-intervention studies, including ECT combined with acupuncture or Chinese herbal medicine, were excluded.

Data extraction {#s2-3}
---------------

Two reviewers (X-ML and Z-MS) independently extracted and checked data. During the data extraction process, disagreements were resolved through discussion and consensus or with the involvement of a senior reviewer (HH). Study authors were contacted by email or telephone to obtain more meta-analysable data. The WebPlotDigitizer V.4.1 (<https://automeris.io/WebPlotDigitizer/>) was used to extract data from figures and/or graphs of the included RCTs as described by a recent meta-analysis.[@R47] Missing SDs were calculated from test statistics or using the mean (SD) of the remaining studies.[@R48] Three RCTs[@R12] with three treatment arms compared propofol with ketamine alone and with ketamine combined with propofol, separately. We included propofol arms twice in the aforementioned respective analyses and used half of the number of patients in the propofol arms.[@R49]

Statistical methods {#s2-4}
-------------------

Two reviewers (X-ML and Z-MS) independently analysed data of the included RCTs using the Review Manager V.5.3 (<http://www.cochrane.org>) based on the PRISMA statement.[@R50] Standardised mean differences (SMDs) with their 95% CIs and risk ratios (RRs) with its 95% CIs were calculated. SMD values over 0.8, 0.5--0.8 and 0.2--0.5 represented large, medium and small effect sizes, respectively.[@R51] All meta-analysable outcomes were pooled using a random effects model.[@R52] The Q statistics and I^2^ were used to assess between-study heterogeneity with a p value of \<0.1 in Q test and I^2^ of ≥50% indicating significant heterogeneity.[@R53] In case of a p value of \<0.1 or I^2^ of ≥50% for the improvement of depressive symptoms at day 1 after a single ECT session, a sensitive analysis was conducted to examine the robustness of meta-analytic results after excluding an outlying study (SMD≤−3.50).[@R17] Funnel plots and Egger's test[@R54] were applied to investigate the possibility of publication bias. All meta-analysable primary and secondary outcomes were considered significant with alpha set at 0.05 (two-sided).

Quality assessment of each included study {#s2-5}
-----------------------------------------

Two reviewers (X-ML and Z-MS) independently conducted quality assessment of each included study using the Cochrane risk of bias[@R55] and the Jadad scale (range = 0--5).[@R56] The Grading of Recommendations, Assessment, Development and Evaluation (GRADE) system[@R57] was applied to examine the overall evidence levels for all meta-analytical outcomes.

Results {#s3}
=======

Search results {#s3-1}
--------------

We identified 209 hits from the aforementioned databases ([figure 1](#F1){ref-type="fig"}); among them, 58 duplicates were removed. Subsequently, 151 articles were screened for titles and abstracts with 136 reports being excluded according to the inclusion and exclusion criteria. Next, 15 full texts were examined with 11 articles being excluded as follows: an S-ketamine study (one trial), multiple ECT sessions (seven trials), a case report (one trial) and conference articles (two trials). Finally, four RCTs with a single ECT session were included in this meta-analysis.[@R12]

![Flowchart of the literature screening.](gpsych-2019-100117f02){#F1}

Study characteristics {#s3-2}
---------------------

Four RCTs (n = 239), which compared ketamine alone or ketamine plus propofol (n = 149) versus propofol alone (n = 90), were included.

### Ketamine versus propofol {#s3-2-1}

Four RCTs (n = 178) compared ketamine alone (n = 88) versus propofol (n = 90). The mean age was 48 (range: 41--55) years in two studies with available data; moreover, 44.8% of the participants (range: 36.7%--51.9%) in three studies with available data were men. None of the studies reported the mean duration of illness ([table 1](#T1){ref-type="table"}).

###### 

Summary of studies included in this meta-analysis

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study\                             Blinding   Diagnostic criteria   Measures on depression   Sex\*: male (%)   Age\* (years) (range)   Intervention group: mean dose (mg/kg), patients (n)                Control group: mean dose (mg/kg), patients (n)   ADs   Observation time (days)   Jadad score
  (country)                                                                                                                                                                                                                                                                                  
  ---------------------------------- ---------- --------------------- ------------------------ ----------------- ----------------------- ------------------------------------------------------------------ ------------------------------------------------ ----- ------------------------- -------------
  Wang *et al*, 2012\                SB         DSM-IV                HAMD                     18†\              56.4†\                  Ketamine (0.8), n = 16Propofol (1.5) plus ketamine (0.8), n = 16   Propofol (1.5), n = 16                           ADs   7                         3
  (China)[@R17]                                                                                (45.0)            (NR)                                                                                                                                                                        

  Xu *et al*, 2013\                  OL         NR                    HAMD                     20\               39.5\                   Ketamine (0.8), n=15Propofol (1.5) plus ketamine (0.8), n=15       Propofol (1.5), n=15                             NR    7                         1
  (China)[@R18]                                                                                (44.4)            (24--60)                                                                                                                                                                    

  Yalcin *et al*, 2012\              NR         NR                    NR                       46\               NR                      Ketamine (10 mg/mL), n = 30Ketofol‡ (10 mg/mL), n = 30             Propofol (10 mg/mL), n=30                        ADs   1                         2
  (Turkey)[@R12]                                                                               (51.1)                                                                                                                                                                                        

  Zhao *et al*, 2016 (China)[@R19]   OL         ICD-10                HAMD                     29\               41.03\                  Ketamine (1.5), n = 27                                             Propofol (2), n = 29                             ADs   1                         2
                                                                                               (51.8)            (NR)                                                                                                                                                                        
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\*Available data were extracted based on mean baseline value of each included trials.

†Number of patients were the data from the completion of the trial because the randomly assigned data were not clear.

‡Ketofol was prepared as a 1:1 mixture of ketamine 10 mg/mL and propofol 10 mg/mL mixed in a 20 mL syringe.

ADs, antideprsants; DSM-IV, *Diagnostic and Statistical Manual of Mental Disorders*, Fourth Edition; HAMD, Hamilton Depression Rating Scale; HDRS, Hamilton Depression Rating Scale; ICD-10, International Statistical Classification of Diseases and Related Health Problems, 10th Revision; n, number of patients; NR, not reported; OL, open label; SB, single blinding.

### Ketamin+propofol versus propofol {#s3-2-2}

Three RCTs (n = 122) compared ketamine+propofol (n = 61) with propofol (n = 61). Only one study with available data reported the mean age (56.5 years); moreover, 39.8% of the participants (range: 36.7%--42.9%) were men in two studies with available data. None of the studies reported the mean illness duration ([table 1](#T1){ref-type="table"}).

Quality assessment {#s3-3}
------------------

In the Cochrane risk of bias ([online supplementary figure 1](#SP1){ref-type="supplementary-material"}), three RCTs (75%, 3/4) were judged as unclear risk with respect to random sequence generation. The Jadad scores ranged from 1 to 3 (mean = 2.0) with only one RCT (25%) being considered as high quality ([table 1](#T1){ref-type="table"}). [Online supplementary table 1](#SP1){ref-type="supplementary-material"} summarises the overall evidence level for all meta-analytic primary and secondary measures, which ranges from very low (26.7%, 4/15) to 'low' (73.3%, 11/15).
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Primary outcomes {#s3-4}
----------------

Ketamine alone was superior to propofol with regard to the improvement of depressive symptoms at days 1 (SMD: −2.37, 95% CI −4.50 to −0.25, I^2^ = 90%, p = 0.03; large effect size), 3 (SMD: −3.94, 95% CI −5.08 to −2.79, I^2^ = 0%, p \< 0.001; large effect size) and 7 (SMD: −2.98, 95% CI −3.94 to −2.01, I^2^ = 0%, p \< 0.001; large effect size) after a single ECT session ([figure 2](#F2){ref-type="fig"}). After excluding an outlying study (SMD≤−3.59),[@R17] the significant difference disappeared (SMD: −1.88, 95% CI −4.49 to 0.74, I^2^ = 92%, p = 0.16).

![The ketamine group versus the propofol group: forest plot for depressive symptoms at days 1, 3 and 7 after a single electroconvulsive therapy session.](gpsych-2019-100117f03){#F2}

Similarly, the combination of ketamine and propofol was superior to propofol with regard to the improvement of depressive symptoms at days 1 (SMD: −2.99, 95% CI −3.94 to −2.04, I^2^ = 0%, p\<0.001; large effect size), 3 (SMD: −3.87, 95% CI −4.97 to −2.77, I^2^ = 0%, p\<0.001; large effect size) and 7 (SMD: −3.08, 95% CI −4.04 to −2.11, I^2^ = 0%, p \< 0.001; large effect size) after a single ECT session ([figure 3](#F3){ref-type="fig"}). None of the studies examined the relationship between ketamine used in ECT and suicide ideation.

![Combination of the ketamine and propofol group versus the propofol group: forest plot for depressive symptoms at days 1, 3 and 7 after a single electroconvulsive therapy session.](gpsych-2019-100117f04){#F3}

Secondary outcomes {#s3-5}
------------------

As shown in [table 2](#T2){ref-type="table"}, ketamine alone was significantly associated with increased seizure duration (SMD: −2.11, 95% CI 1.54 to 2.67, I^2^=0%, p\<0.001; large effect size), seizure energy index (SMD: −1.74, 95% CI 0.97 to 2.51, I^2^=0%, p\<0.001; large effect size) and eye-opening time (SMD: 2.73, 95% CI 1.53 to 3.94, I^2^=64%, p\<0.001; large effect size) compared with propofol.

###### 

Secondary outcomes

  Secondary outcomes                       Subjects (active treatment arms)   SMDs or RRs (95% CI)   I^2^ (%)   P value
  ---------------------------------------- ---------------------------------- ---------------------- ---------- -------------
  Ketamine versus propofol                                                                                      
   Seizure duration (s)                    86 (3)                             -2.11 (1.54 to 2.67)   0          **\<0.001**
   Seizure energy index (uv2)              41 (2)                             -1.74 (0.97 to 2.51)   0          **\<0.001**
   Open eyes (min)                         68 (2)                             2.73 (1.53 to 3.94)    64         **\<0.001**
   Hypertension                            92 (3)                             1.31 (0.58 to 2.93)    0          0.51
   Nausea and vomiting                     92 (3)                             1.19 (0.34 to 4.20)    0          0.78
  Ketamine plus propofol versus propofol                                                                        
   Seizure duration (s)                    89 (3)                             -2.11 (0.55 to 3.67)   84         **0.008**
   Seizure energy index (uv2)              44 (2)                             -1.71 (0.95 to 2.47)   0          **\<0.001**
   Open eyes (min)                         67 (2)                             1.78 (-0.31 to 3.86)   88         0.09
   Hypertension                            91 (3)                             0.81 (0.33 to 2.00)    0          0.65

Boldfaced values: data was considered to have significant differences when p \< 0.05.

RR, risk ratio; SMD, standardised mean difference.

Similarly, ketamine combined with propofol was significantly associated with increased seizure duration (SMD: −2.11, 95% CI 0.55 to 3.67, I^2^=84%, p=0.008; large effect size) and seizure energy index (SMD: −1.71, 95% CI 0.95 to 2.47, I^2^=0%, p\<0.001; large effect size) compared with propofol. There was no group difference in the eye-opening time (SMD: 1.78, 95% CI −0.31 to 3.86, I^2^=88%, p=0.09; large effect size).

There was no significant difference regarding hypertension between propofol and ketamine alone (p=0.51) and between propofol and ketamine combined with propofol (p=0.65). There was no group difference regarding nausea and vomiting between ketamine and propofol alone (p=0.78) ([table 2](#T2){ref-type="table"}).

Publication bias {#s3-6}
----------------

Publication bias was not evaluated for all outcomes because a minimum of 10 RCTs are needed to perform funnel plot or Egger's test.[@R59]

Discussion {#s4}
==========

Main findings {#s4-1}
-------------

This is the first meta-analysis to examine the effectiveness and safety of ketamine alone or ketamine combined with propofol in patients with MDD undergoing a single ECT session. Ketamine alone and ketamine combined with propofol were more efficacious than propofol alone as an ECT anaesthesia in treating depressive symptoms at days 1, 3 and 7 after a single ECT session with large effect size.[@R51] However, the significant superiority of ketamine to propofol alone in improving depressive symptoms was driven by an outlying study.[@R17] Compared with propofol, ketamine alone and the combination of ketamine and propofol significantly increased the seizure duration and seizure energy index. Furthermore, ketamine alone, but not ketamine combined with propofol, could significantly increase opening-eye time compared with propofol. However, a recent study found that ketamine as an anaesthetic did not enhance the antidepressant effects of six ECT treatments.[@R45]

Limitations {#s4-2}
-----------

This study has several limitations. Firstly, the number of included RCTs and sample size of each included RCT were relatively small, which impeded more comprehensive analyses, including subgroup and meta-regression analyses. Secondly, the significant heterogeneity in the meta-analytic findings for the primary outcome could be partly attributed to each included study with differences in methodological characteristics, including the dosage of propofol and ketamine, electrode placements and patient property. Further, future studies should compare between single and multiple ECT sessions for MDD. Finally, none of the RCTs reported randomisation methods with a specific description as measured by the Cochrane risk of bias; moreover, three RCTs (75%, 3/4) were rated as low quality as measured by the Jadad scale. Furthermore, quality of evidence for all meta-analytic outcomes was considered as 'very low' or low according to the GRADE approach. However, as suggested by Guyatt *et al*.,[@R60] low-quality evidence could still lead to strong recommendations.

Implications {#s4-3}
------------

We found that ECT-treated patients with MDD receiving ketamine plus propofol or ketamine alone had more significant improvements in depressive symptoms compared with patients receiving propofol alone. This suggests that ketamine alone or the combination of ketamine and propofol as an ECT anaesthesia has an early and rapid antidepressant effect superior to that of propofol anaesthesia, which was consistent with the findings of previous meta-analyses indicating that ketamine has rapid antidepressant effects.[@R9]

Two previous meta-analyses[@R20] reported that ketamine used in ECT did not reduce the depressive symptoms at the end of the treatment; however, it could accelerate the antidepressive effects in depressive patients undergoing ECT. Thus, ketamine use in ECT has considerable clinical significance because the delayed onset of antidepressant effects is closely associated with prolonged severe morbidity suicide risk.[@R61] However, none of the included RCTs assessed the antisuicidal effects of ketamine used in ECT. The incidence of hypertension was similar in the ketamine group and ketamine combined with the propofol group compared with the propofol group. Thus, the use of ketamine and ketamine combined with propofol is safe and tolerable.

As expected, there were significant difference regarding the seizure activity duration and the seizure energy index between propofol and ketamine alone, and ketamine combined with propofol. Interestingly, the combination of ketamine and propofol group was not associated with longer mean eye-opening time compared with the propofol group. Thus, the use of ketamine plus propofol as an ECT anaesthesia might be advantageous for analgesia and haemodynamic stability.[@R12] Notably, ketamine-related nauseant and psychomimetic effects could be counterbalanced by the sedative and antiemetic effects of propofol. Given the potential balance of effects, the combination of ketamine and propofol as an ECT anaesthesia is superior to either agent alone.[@R12]

Conclusion {#s5}
==========

According to very low or low evidence level, compared with propofol alone, ketamine alone and the combination of ketamine and propofol have an advantage in rapidly improving depressive symptoms of patients with MDD undergoing a single ECT session. Due to significant heterogeneity and small sample size, high-quality RCTs are required to confirm and extend these findings.
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